Evolus (EOLS) Cash from Investing Activities Growth (1y) (2019 - 2026)
Evolus (EOLS) Cash from Investing Activities Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Evolus | 550.51 Mn | 505.34 Mn | 57.18 Mn | 77.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.94% |
| Mar 31, 2026 | 9.13% |
| Dec 31, 2025 | -59.03% |
| Sep 30, 2025 | -53.05% |
| Jun 30, 2025 | -80.78% |
| Mar 31, 2025 | -133.50% |
| Dec 31, 2024 | -277.29% |
| Sep 30, 2024 | -161.60% |
| Jun 30, 2024 | -480.56% |
| Mar 31, 2024 | -55.97% |
| Dec 31, 2023 | 74.05% |
| Sep 30, 2023 | 40.04% |
| Jun 30, 2023 | 44.33% |
| Mar 31, 2023 | -95.79% |
| Dec 31, 2022 | -256.67% |
| Sep 30, 2022 | -4,380.95% |
| Jun 30, 2022 | -0.52% |
| Mar 31, 2022 | -105.45% |
| Dec 31, 2021 | -101.98% |
| Sep 30, 2021 | -99.93% |